In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.

在丙感染者中，重叠感染隐匿性HBV会影响干扰素的疗效。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并硬化的慢性丙（CHC）患者接受α干扰素包括派罗欣治疗时存在功能失代偿风险。